Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo
about
MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition.Matrix stiffness affects endocytic uptake of MK2-inhibitor peptidesEphrin type-B receptor 4 activation reduces neointimal hyperplasia in human saphenous vein in vitro.Endosomolytic Nano-Polyplex Platform Technology for Cytosolic Peptide Delivery To Inhibit Pathological Vasoconstriction.Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical TrialsMK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia.Cell-permeant peptide inhibitors of vasospasm and intimal hyperplasia.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia.Biomaterial-Based Approaches to Address Vein Graft and Hemodialysis Access Failures.Characterization of endocytic uptake of MK2-inhibitor peptides.Advanced glycation end products impair the functions of saphenous vein but not thoracic artery smooth muscle cells through RAGE/MAPK signalling pathway in diabetes.The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinases (MAPKAPKs) in Inflammation.Improving the Outcome of Vein Grafts: Should Vascular Surgeons Turn Veins into Arteries?MMI-0100 Inhibits Cardiac Fibrosis in a Mouse Model Overexpressing Cardiac Myosin Binding Protein C.Heparin-functionalized polymer graft surface eluting MK2 inhibitory peptide to improve hemocompatibility and anti-neointimal activity.Collagen-binding nanoparticles for extracellular anti-inflammatory peptide delivery decrease platelet activation, promote endothelial migration, and suppress inflammation.Excipients for the lyoprotection of MAPKAP kinase 2 inhibitory peptide nano-polyplexes.
P2860
Q27302407-FEE2B7A7-2E9F-4E57-9F3E-6E70CDEB3C2DQ28538331-DE98CD41-3C87-4261-9795-5623ECFF81AEQ35536905-6CD4C2D7-2E6C-475F-93E6-14EE6B108345Q35787259-63A91323-B7D6-4DAA-931D-1C1781622555Q36849634-CF678DC1-C7D6-46DE-B3CA-E244B0A947D5Q37727105-7145FF7D-3980-44D5-9203-91E54BB627DFQ38056103-1C91FE8A-B615-4B22-BE8B-596379BE7BAEQ38580461-94E42897-B903-4D77-9F4A-0C30BB8A7DFDQ38739534-2D847473-8A0D-437C-BE84-268BEF9F50C8Q38817264-1602D8D8-E261-4E75-8E9C-91377644740FQ39964130-1DD55442-F85F-4C69-961C-B5632240544EQ41074576-0254DA83-39F7-46CD-AE28-7F2FB23104D9Q41887469-33A7D634-3412-48A3-819E-4C17257FA43BQ42352727-0307E0CC-1224-4A1D-81EC-CF16C0727560Q42373740-D41C1E78-52E3-4261-9041-DE7CDE842D50Q47592103-4AC59D10-DDEE-4893-AC29-AB57FFCD0520Q51101323-1E654DBA-2C00-4267-A343-AB24717B04B8Q52715623-6440F6A2-5173-48F2-9F36-9C227F17AF46
P2860
Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Inhibition of Mitogen Activate ...... yperplasia ex vivo and in vivo
@ast
Inhibition of Mitogen Activate ...... yperplasia ex vivo and in vivo
@en
type
label
Inhibition of Mitogen Activate ...... yperplasia ex vivo and in vivo
@ast
Inhibition of Mitogen Activate ...... yperplasia ex vivo and in vivo
@en
prefLabel
Inhibition of Mitogen Activate ...... yperplasia ex vivo and in vivo
@ast
Inhibition of Mitogen Activate ...... yperplasia ex vivo and in vivo
@en
P2093
P2860
P1476
Inhibition of Mitogen Activate ...... yperplasia ex vivo and in vivo
@en
P2093
Akihito Muto
Alan Dardik
Alyssa Panitch
Colleen M Brophy
Kinam Park
Padmini Komalavilas
P2860
P356
10.1016/J.VPH.2011.07.008
P577
2011-10-17T00:00:00Z